2025 Packaging Pharmaceutical Companies 
European Pharmaceutical Review
NOVEMBER 1, 2024
The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12 billion in 2025 to approximately $174.45 billion by 2033, according to a study published by Towards Packaging. Specifically, the “high quality of biodegradable and recyclable packaging materials” are driving the market.
Pharma Marketing Network
DECEMBER 4, 2024
As we approach 2025, emerging trends are reshaping how the industry engages with patients and healthcare providers. From eco-friendly packaging to socially responsible campaigns, sustainability resonates with today’s consumers. Learn more about compliance tips at Pharma Marketing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
DECEMBER 30, 2024
Jayakumar gave examples of common issues, such as packaging damage or consistency problems in ointments, stressing the importance of not dismissing seemingly minor complaints, as they could escalate into more significant quality issues.
Express Pharma
MARCH 16, 2025
In India, pharmaceutical companies responded to global environmental concerns and government mandates by adopting greener manufacturing techniques. Indian pharmaceutical companies have specialised in reverse-engineering complex medicines and producing biosimilars as alternatives to costly biologics.
Pharmaceutical Technology
JUNE 19, 2023
Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Products are stored and packaged in a dedicated suite by a dedicated team,” explains MacNeir.
Pharmaceutical Technology
MAY 23, 2023
The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. While a handful of incentives are offered by the reform package, they are overshadowed by the potential drawbacks for the innovative sector.
PharmaShots
JUNE 7, 2023
To further expedite the introduction of the biosimilar globally, EirGenix has been in talks with global pharmaceutical companies about licensing the marketing rights to EG1206A 5. The P-III trial of EG1206A is expected to be initiated shortly, estimated that the evaluation of the primary EPs will be completed within 2yrs.
Expert insights. Personalized for you.
52 
Let's personalize your content